QuidelOrtho Corporation $QDEL Shares Sold by Lightrock Netherlands B.V.

Lightrock Netherlands B.V. cut its position in shares of QuidelOrtho Corporation (NASDAQ:QDEL) by 31.8% during the first quarter, HoldingsChannel.com reports. The institutional investor owned 314,547 shares of the company’s stock after selling 146,453 shares during the quarter. Lightrock Netherlands B.V.’s holdings in QuidelOrtho were worth $5,168,000 as of its most recent filing with the SEC.

Other hedge funds have also recently added to or reduced their stakes in the company. Goodman Financial Corp increased its holdings in QuidelOrtho by 12.5% in the first quarter. Goodman Financial Corp now owns 437,157 shares of the company’s stock valued at $7,182,000 after buying an additional 48,405 shares in the last quarter. Illinois Municipal Retirement Fund boosted its stake in shares of QuidelOrtho by 24.9% during the 1st quarter. Illinois Municipal Retirement Fund now owns 43,751 shares of the company’s stock worth $719,000 after acquiring an additional 8,723 shares in the last quarter. Principal Financial Group Inc. grew its position in shares of QuidelOrtho by 2.1% during the 1st quarter. Principal Financial Group Inc. now owns 331,184 shares of the company’s stock valued at $5,441,000 after acquiring an additional 6,955 shares during the period. Fifth Third Bancorp increased its stake in shares of QuidelOrtho by 42,014.7% in the 1st quarter. Fifth Third Bancorp now owns 54,328 shares of the company’s stock valued at $893,000 after purchasing an additional 54,199 shares in the last quarter. Finally, Hsbc Holdings PLC purchased a new position in shares of QuidelOrtho in the 1st quarter valued at about $342,000. 99.00% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

A number of equities analysts have issued reports on the company. UBS Group reiterated a “neutral” rating and set a $12.00 price target on shares of QuidelOrtho in a research report on Thursday, May 7th. JPMorgan Chase & Co. upped their target price on QuidelOrtho from $11.00 to $12.00 and gave the stock an “underweight” rating in a research note on Wednesday, July 1st. Wall Street Zen upgraded QuidelOrtho from a “sell” rating to a “hold” rating in a research report on Sunday, June 28th. Jefferies Financial Group reissued a “hold” rating on shares of QuidelOrtho in a research note on Monday, June 29th. Finally, Weiss Ratings reissued a “sell (e+)” rating on shares of QuidelOrtho in a report on Tuesday, April 21st. Four equities research analysts have rated the stock with a Hold rating and two have given a Sell rating to the stock. According to MarketBeat.com, QuidelOrtho has an average rating of “Reduce” and an average target price of $13.62.

QuidelOrtho Stock Up 0.1%

Shares of QDEL opened at $18.24 on Friday. The stock has a 50 day moving average price of $14.17 and a 200 day moving average price of $19.17. QuidelOrtho Corporation has a one year low of $9.92 and a one year high of $35.58. The company has a debt-to-equity ratio of 1.33, a quick ratio of 0.80 and a current ratio of 1.43. The stock has a market capitalization of $1.24 billion, a price-to-earnings ratio of -1.02 and a beta of 0.69.

QuidelOrtho (NASDAQ:QDEL) last announced its quarterly earnings data on Tuesday, May 5th. The company reported ($0.04) earnings per share for the quarter, missing analysts’ consensus estimates of $0.37 by ($0.41). QuidelOrtho had a negative net margin of 45.57% and a positive return on equity of 4.25%. The firm had revenue of $619.80 million during the quarter, compared to analysts’ expectations of $665.23 million. During the same quarter in the previous year, the business posted $0.74 EPS. The company’s revenue for the quarter was down 10.5% on a year-over-year basis. QuidelOrtho has set its FY 2026 guidance at 1.800-2.000 EPS. Equities research analysts forecast that QuidelOrtho Corporation will post 1.87 earnings per share for the current fiscal year.

QuidelOrtho Profile

QuidelOrtho is a global diagnostics company formed through the merger of Quidel Corporation and Ortho Clinical Diagnostics. The combined entity develops, manufactures and markets a broad portfolio of rapid and high-throughput diagnostic solutions across immunoassay, molecular diagnostics and transfusion medicine. Its offerings span point-of-care platforms for acute care testing as well as large-scale automated systems designed for clinical laboratories and blood banks.

The company’s product range includes rapid antigen and antibody tests for infectious diseases, molecular assays utilizing nucleic acid amplification technology, and integrated immunodiagnostic analyzers.